Identification of dose sensitive cardiac subregions associated with overall survival
Name:
36738929.pdf
Size:
501.8Kb
Format:
PDF
Description:
Identified with Open Access button
Affiliation
The Division of Cancer Science, The University of Manchester, Manchester, United KingdomIssue Date
2023
Metadata
Show full item recordAbstract
Introduction: The RTOG 0617 trial presented a worse survival for patients with lung cancer treated in the high-dose (74 Gy) arm. In multivariable models, radiation level and whole-heart volumetric dose parameters were associated with survival. In this work, we consider heart subregions to explain the observed survival difference between radiation levels. Methods: Voxel-based analysis identified anatomical regions where the dose was associated with survival. Bootstrapping clinical and dosimetric variables into an elastic net model selected variables associated with survival. Multivariable Cox regression survival models assessed the significance of dose to the heart subregion, compared with whole heart v5 and v30. Finally, the trial outcome was assessed after propensity score matching of patients on lung dose, heart subregion dose, and tumor volume. Results: A total of 458 patients were eligible for voxel-based analysis. A region of significance (p < 0.001) was identified in the base of the heart. Bootstrapping selected mean lung dose, radiation level, log tumor volume, and heart region dose. The multivariable Cox model exhibited dose to the heart region (p = 0.02), and tumor volume (p = 0.03) were significantly associated with survival, and radiation level was not significant (p = 0.07). The models exhibited that whole heart v5 and v30 were not associated with survival, with radiation level being significant (p < 0.05). In the matched cohort, no significant survival difference was seen between radiation levels. Conclusions: Dose to the base of the heart is associated with overall survival, partly removing the radiation level effect, and explaining that worse survival in the high-dose arm is owing, in part, to the heart subregion dose. By defining a heart avoidance region, future dose escalation trials may be feasible.Citation
McWilliam A, Abravan A, Banfil K, Faivre-Finn C, van Herk M. Identification of Dose Sensitive Cardiac Subregions Associated With Overall Survival. Journal of Thoracic Oncology. 2023 May;18(5):599-607. PubMed PMID: WOS:000984197600001.Journal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2023.01.085PubMed ID
36738929Additional Links
https://dx.doi.org/10.1016/j.jtho.2023.01.085Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2023.01.085
Scopus Count
Collections
Related articles
- Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer.
- Authors: Wang K, Pearlstein KA, Patchett ND, Deal AM, Mavroidis P, Jensen BC, Lipner MB, Zagar TM, Wang Y, Lee CB, Eblan MJ, Rosenman JG, Socinski MA, Stinchcombe TE, Marks LB
- Issue date: 2017 Nov
- Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer.
- Authors: Speirs CK, DeWees TA, Rehman S, Molotievschi A, Velez MA, Mullen D, Fergus S, Trovo M, Bradley JD, Robinson CG
- Issue date: 2017 Feb
- Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
- Authors: Pokhrel D, Sood S, Badkul R, Jiang H, McClinton C, Lominska C, Kumar P, Wang F
- Issue date: 2016 May 8
- Cardiac Dose in Locally Advanced Lung Cancer: Results From a Statewide Consortium.
- Authors: Dess RT, Sun Y, Muenz DG, Paximadis PA, Dominello MM, Grills IS, Kestin LL, Movsas B, Masi KJ, Matuszak MM, Radawski JD, Moran JM, Pierce LJ, Hayman JA, Schipper MJ, Jolly S, Michigan Radiation Oncology Quality Consortium
- Issue date: 2020 Jan-Feb
- Doses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancer.
- Authors: Xue J, Han C, Jackson A, Hu C, Yao H, Wang W, Hayman J, Chen W, Jin J, Kalemkerian GP, Matuzsak M, Jolly S, Kong FS
- Issue date: 2019 Apr